Home » Topics » BioWorld Science

BioWorld Science
RSS

FDA approves Ruzurgi for pediatric patients with Lambert-Eaton myasthenic syndrome

May 7, 2019

Simple, reversible mouse model mimics secondary glaucoma

May 7, 2019

CytoDyn reports data from leronlimab monotherapy study

May 7, 2019

Phase III trial of Epidiolex in TSC meets primary endpoint

May 7, 2019

First patient dosed in phase I DUET-3 study of XmAb-23104

May 7, 2019

Axsome announces expedited development and pivotal status for AXS-05 for the treatment of MDD

May 7, 2019

DSMB recommends continuation of phase I/II PIONEER study of GS-030 in retinitis pigmentosa

May 7, 2019

Verona initiates phase IIb study of nebulized ensifentrine in moderate to severe COPD

May 7, 2019

Onxeo treats first patient in phase Ib study of AsiDNA for solid tumors

May 7, 2019

Sunshine Lake Pharma divulges compounds for HBV infections

May 7, 2019

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...